Elisa Paolicchi
Pisa, 56126, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Journal: Investigational new drugs
Published: September 14, 2020
DNA repair and cancer in colon and rectum: Novel players in genetic susceptibility.
Journal: International journal of cancer
Published: February 25, 2019
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
Journal: Occupational and environmental medicine
Published: August 16, 2016
Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk.
Journal: Scientific reports
Published: October 29, 2014
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk.
Journal: The Journal of clinical endocrinology and metabolism
Published: July 17, 2014
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients.
Journal: Pharmacogenomics
Published: May 07, 2014
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Journal: Molecular cancer therapeutics
Published: May 25, 2012
An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw.
Journal: Biomarkers in medicine
Published: March 28, 2012
Last Updated: 09/26/2026